PET/MR for therapy response evaluation in malignant lymphoma: initial experience. - Wikidata - wikimedia - TriplyDB

PET/MR for therapy response evaluation in malignant lymphoma: initial experience.

PET/MR for therapy response evaluation in malignant lymphoma: initial experience.

http://www.wikidata.org/entity/Q36609749

about

Clinical and research applications of simultaneous positron emission tomography and MRI Attenuation correction for flexible magnetic resonance coils in combined magnetic resonance/positron emission tomography imaging.Clinical applications of PET/MRI: current status and future perspectives.Integrated whole body MR/PET: where are we?PET/MRI for the evaluation of patients with lymphoma: initial observations.Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT.Primary Pulmonary Diffuse Large B-Cell Lymphoma on FDG PET/CT-MRI and DWI Orbital tumours and tumour-like lesions: exploring the armamentarium of multiparametric imaging 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging Surveillance imaging in pediatric Hodgkin Lymphoma.Initial experience of MR/PET in a clinical cancer center.Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI.How PET/MR Can Add Value For Children With Cancer.Speeding up PET/MR for cancer staging of children and young adults.Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol.MR/PET or PET/MRI: does it matter?Hybrid PET/MR: Updated Clinical Use and Potential Applications

P2860

Q26998774-F9727C52-137A-4290-A8D3-F77775A714A0 Q30668738-7D699185-2C51-4F06-9E66-3AF65BB00763 Q30835897-A2E2E97C-DD21-4265-A5D0-F505D8493B61 Q34975185-97EE9272-115B-4BC7-8F68-0195298A056B Q35737190-68471683-B99F-48EE-B654-B80BA38F986A Q35877119-2EB45789-6F9A-40A5-9956-01BA84067ADF Q36153490-26E8BFDB-822C-4701-9AE9-3DBCDFA8028D Q36510658-E7401051-E7A2-424F-9562-DFAFC7EE7505 Q36564214-94AE5586-BC4B-4395-AA20-7608E09C9EFA Q38119890-A3CD68B3-BE5A-4995-9580-9B98D0108C54 Q38134357-A55A8EDF-5F5C-4F60-9225-2CE7D3DE34CA Q38680358-106B34B3-D3D6-4144-BE06-4A9F29AF5308 Q39427334-0A2CA9CE-65B0-4786-BD9B-9674C2E25384 Q39860692-A591B006-E6A0-4D5B-946D-727396C2018E Q41207387-39826CD1-261F-4912-9AFB-E9742B7BB89F Q43639655-099F4ED2-CACE-40D7-B53E-601418C16BDC Q58109703-0AD2B0E7-C71C-44EF-A6A6-B78480C5B320

P2860

PET/MR for therapy response evaluation in malignant lymphoma: initial experience.

http://www.wikidata.org/entity/Q36609749

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

PET/MR for therapy response evaluation in malignant lymphoma: initial experience.

@ast

PET/MR for therapy response evaluation in malignant lymphoma: initial experience.

@en

type

label

PET/MR for therapy response evaluation in malignant lymphoma: initial experience.

@ast

PET/MR for therapy response evaluation in malignant lymphoma: initial experience.

@en

prefLabel

PET/MR for therapy response evaluation in malignant lymphoma: initial experience.

@ast

PET/MR for therapy response evaluation in malignant lymphoma: initial experience.

@en

P1433

Q36609749-726B3B35-E5AF-49C7-9FB7-034962B86B37

P1476

Q36609749-1C17AC9F-623E-4456-8D9F-AE642BA7D4BC

P2093

Q36609749-12FC76AD-349B-463C-8320-869DC8A35ABA

Q36609749-14083654-FC3B-46A3-ACEA-4E8E0B470BD3

Q36609749-2D9A60FC-60F0-483F-B9A7-92B14C91F2FA

Q36609749-44B38E0C-0415-405E-8FA5-2F2E264F8C14

Q36609749-52FC03D5-B080-42FD-9EE9-950E97F30553

Q36609749-BE9B560A-6284-48D6-B0C3-9FB94FCC9C09

Q36609749-C31B02C0-799A-4692-BE84-4FFBC0D47C61

Q36609749-FA65BCFF-90B6-4C61-B888-B8862F21100D

P2860

Q36609749-0FC6A3EA-782B-45F5-B089-4FF08E15C44E

Q36609749-2D5A8039-57E0-47AC-A096-3D34E348181E

Q36609749-3848668F-C1A7-4BEF-A164-C98FEEBB1C14

Q36609749-5D25B6FF-AE13-4CDE-AECF-C75FEB7744CE

Q36609749-6063DB47-AFF3-4A70-81E0-C473380E17A0

Q36609749-6D084022-4F67-4BFC-B2F3-5FBA93E87207

Q36609749-A82A8B28-0C89-4901-A798-A166452CD01F

Q36609749-C2120D02-1758-44FF-933A-23AA0C2D052E

Q36609749-C4D2A3D5-29BB-416B-A0DA-9E64C36AE68D

Q36609749-DB8A7BB9-8296-4982-AF0B-C6783A7B0030

P2888

Q36609749-DA75B177-1252-4237-B73B-B3598D673FE2

P304

Q36609749-0887ECFE-1680-4ACC-B9B9-1C2C1F5FF183

P31

Q36609749-492FA828-915A-4021-8677-0ABCE6D40661

P356

Q36609749-A41217CC-FBE9-4B98-9A42-15567CB805E0

P433

Q36609749-C261C162-6130-45C4-AF5A-D5CD36F67031

P478

Q36609749-972A4946-25C3-4B9F-B5A3-82AD22E7B0D1

P50

Q36609749-C64BD79D-3871-456B-8A46-A72DF612B48B

P577

Q36609749-1F49F2E4-592F-414E-B2A7-F24B55304947

P5875

Q36609749-0BBF7CEB-B70F-4114-A235-A173F3AF3DE9

P698

Q36609749-4FF71EF4-0A55-4EE9-A0B0-FE12FEF6B27C

P932

Q36609749-67D54F6C-A6B4-4F2A-A877-4FE04B2291CB

P356

S10334-012-0342-7

P1433

Magnetic Resonance Materials in Physics, Biology and Medicine

P1476

PET/MR for therapy response evaluation in malignant lymphoma: initial experience

@en

P2093

Bettina Beuthien-Baumann

http://www.w3.org/2001/XMLSchema#string

Ivan Platzek

http://www.w3.org/2001/XMLSchema#string

Jens Langner

http://www.w3.org/2001/XMLSchema#string

Jörg Kotzerke

http://www.w3.org/2001/XMLSchema#string

Jörg van den Hoff

http://www.w3.org/2001/XMLSchema#string

Manuel Popp

http://www.w3.org/2001/XMLSchema#string

Michael Laniado

http://www.w3.org/2001/XMLSchema#string

Rainer Ordemann

http://www.w3.org/2001/XMLSchema#string

P2860

Report of the Committee on Hodgkin's Disease Staging Classification

Design and performance evaluation of a whole-body Ingenuity TF PET-MRI system.

A combined PET/CT scanner for clinical oncology.

Radiation exposure and mortality risk from CT and PET imaging of patients with malignant lymphoma.

Quantitative accuracy of attenuation correction in the Philips Ingenuity TF whole-body PET/MR system: a direct comparison with transmission-based attenuation correction

Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?

Imaging in staging of malignant lymphoma: a systematic review.

First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses.

P2888

s10334-012-0342-7

P304

49-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10334-012-0342-7

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230864270

http://www.w3.org/2001/XMLSchema#string

P698

22983794

http://www.w3.org/2001/XMLSchema#string

P932

3572376

http://www.w3.org/2001/XMLSchema#string